Skip to main content
Albert LoBuglio, MD, Oncology, Birmingham, AL

AlbertF.LoBuglioMD

Oncology • Birmingham, AL

Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Are you Dr. LoBuglio?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 35 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Albert LoBuglio, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama. He is a Professor at University of Alabama School of Medicine.

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1965 - 1967
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 1963 - 1965
  • UPMC Medical Education
    UPMC Medical EducationInternship, Transitional Year, 1962 - 1963
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1962

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 1983 - 2015

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1974

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Closing the Gap
    Closing the GapNovember 3rd, 2022
  • Cancer Disparities Through the Decades
    Cancer Disparities Through the DecadesJune 10th, 2022
  • Personalized Medicine: UAB Breast Cancer Research Works Toward Focused Treatments
    Personalized Medicine: UAB Breast Cancer Research Works Toward Focused TreatmentsOctober 6th, 2016

Grant Support

  • Comprehensive Cancer Center Core Support GrantNational Cancer Institute1995–2003
  • Novel Radioimmunotherapy For Ovarian CancerNational Cancer Institute2000–2002
  • Targeted Immunotherapy ProgramNational Cancer Institute1999–2002
  • Interferon Enhanced Intraperitoneal Radioimmunity For Ovarian CancerNational Center For Research Resources1997–2002
  • Rituxan In Treatment Of Immune Thrombocytopenic PurpuraNational Center For Research Resources2000
  • Idec-Y902b8 Radioimmunotherapy: Relapsed B Cell LymphomaNational Center For Research Resources2000
  • Recombinant Vaccinia CEA (70DD) Vaccine In Low Tumor Burden Colorectal CancerNational Center For Research Resources1998–2000
  • Onco Vax CL In Colorectal CancerNational Center For Research Resources1998–2000
  • Imaging Trial Of 3622w94National Center For Research Resources1998–2000
  • Renovation Of Space In Volker HallNational Center For Research Resources1999
  • Bms191352 In Advanced CarcinomaNational Center For Research Resources1997–1999
  • Recombinant Tumor Vaccine--CatbrmNational Cancer Institute1996–1999
  • Core--Institutional ProtocolsNational Cancer Institute1996–1999
  • Core--Developmental FundsNational Cancer Institute1996–1999
  • Clinical Trials Of Biological Response Modifiers-Task ANational Cancer Institute1996–1999
  • Safety And Pharmacokinetics Of 3622w94National Center For Research Resources1997
  • Recombinant Vaccinia-Cea (70DD) Vaccine In Low Tumor Burden AdenocarcinomaNational Center For Research Resources1997
  • Completion Of Shell Space For Genetics CenterNational Center For Research Resources1997
  • Bms-182248(Br96-Doxorubicin Conjugate) In Patients With Advanced CarcinomaNational Center For Research Resources1997
  • Recombinant Rv-Cea In Low Tumor Burden Adenocarcinoma Of The ColonNational Center For Research Resources1996
  • R CEA Immunogen In Metastatic Adenocarcinoma Of The BreastNational Center For Research Resources1996
  • Bms-182248 In Patients With Advanced CarcinomaNational Center For Research Resources1996
  • Clinical Trials Of Biological Response ModifiersDivision Of Cancer Treatment1995–1996
  • Tumor Vaccine CatbrmNational Cancer Institute1993–1995
  • Monoclonal Antibodies And Other Targeting AgentsDivision Of Cancer Treatment1989–1994
  • Cancer Center Core Support GrantNational Cancer Institute1985–1994
  • Construction Grant For Rodent Barrier UnitNational Cancer Institute1992
  • Human Immune Cytopenias--Monoclonal AntibodiesNational Institute Of Allergy And Infectious Diseases1989–1991
  • Radiolabeled Chimeric Monoclonal Antibody (C-17-1a) Colon CancerNational Center For Research Resources1990
  • Phase I 131-1 Lym-1 Patients With Diffuse Aggressive LymphomasNational Center For Research Resources1990
  • IV 131I Labeled Chimeric Igg4 B72.3 In Advanced Colorectal CarcinomaNational Center For Research Resources1990
  • Chimeric Monoclonal Anti-Gd2 Antibody 14.18 In Metastatic MelanomaNational Center For Research Resources1990
  • Hematology Training ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
  • Human Immune Cytopenias-Studies With Monoclonal AntibodyNational Institute Of Allergy And Infectious Diseases1985–1988
  • Melanoma Tumor Detection Using III Inlabeled Monoclonal Antibody Type 96.5National Center For Research Resources1985
  • Colon Cancer Tumor Imaging Using Iii-Indium Labeled Monoclonal Antibody Zce 025National Center For Research Resources1985
  • Core Facilites--Outpatient Nursing UnitNational Cancer Institute1985
  • Cancer Center Core Support Grant (COMPREHENSIVE)National Cancer Institute1985
  • Hematology Training ProgramNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985

Dr. Albert LoBuglio, Dr. Albert LoBuglio, MD, Dr. A LoBuglio, Dr. Albert F. LoBuglio